Intelligent Bio Solutions Inc. (INBS) shareholders
Close on Nov 17, 2026Market cap $4.72MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Anand Parekh Joint filing with Alyeska Investment Group, L.P. (9.99%), Alyeska Fund GP, LLC (9.99%) | 944,310 | 9.99% | 13G (passive) amendment | Sep 30, 2025 |
| Steven Boyd Joint filing with Armistice Capital, LLC (5.91%) | 141,397 | 5.91% | 13G (passive) amendment | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of INBS | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Armistice Capital, LLC | 141,397 | 4.67% | $324.51K | +11,397 | 0.00% |
| Geode Capital Management, LLC | 20,840 | 0.69% | $47.83K | −7,769 | 0.00% |
| Vanguard Capital Management LLC | 5,810 | 0.19% | $13.33K | – | 0.00% |
| UBS Group AG | 5,735 | 0.19% | $13.16K | +5,363 | 0.00% |
| Vanguard Fiduciary Trust Co | 3,958 | 0.13% | $9.08K | – | 0.00% |
| Tower Research Capital LLC (TRC) | 3,280 | 0.11% | $7.53K | +2,030 | 0.00% |
| Osaic Holdings, Inc. | 200 | 0.01% | $460 | – | 0.00% |
| Barclays PLC | 142 | 0.00% | $326 | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 8 | 0M | 6.0% | 1 / 3 | 1 / 2 | 0M | 0M |
| Q1 2026 | 9 | 0M | 6.9% | 6 / 0 | 2 / 4 | 0M | 0M |
| Q4 2025 | 7 | 0M | 0.2% | 7 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
5 funds held INBS in Q2 2026, 28% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of INBS | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 12,545 | 0.41% | $32.24K | 0.00% | May 31, 2026 |
| Vanguard Extended Market Index Fund | 5,810 | 0.19% | $13.33K | 0.00% | Jun 30, 2026 |
| Fidelity Series Total Market Index Fund | 1,769 | 0.06% | $4.55K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 409 | 0.01% | $1.05K | 0.00% | May 31, 2026 |
| Blackstone Alternative Multi-Strategy Fund | -30 | -0.00% | -$69 | -0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Harry Simeonidis | Chief Executive Officer | 34,540 | 1.14% | Mar 20, 2026 |
| Spiro Kevin Sakiris | Chief Financial Officer | 35,892 | 1.19% | Mar 20, 2026 |
| Steven Constantine Boyages | Director | 5,031 | 0.17% | Mar 20, 2026 |
| Jonathan Scott Hurd | Director | 5,006 | 0.17% | Mar 20, 2026 |
| Jason Isenberg | Director | 5,000 | 0.17% | Mar 20, 2026 |
| Nicola Marion Fraser | Director | 5,000 | 0.17% | Mar 20, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Harry Simeonidis Chief Executive Officer | Mar 18, 2026 | Award | +21,350 | – | – | 34,540 |
| Harry Simeonidis Chief Executive Officer | Mar 18, 2026 | Award | +9,150 | – | – | 13,190 |
| Jason Isenberg Director | Mar 18, 2026 | Award | +5,000 | – | – | 5,000 |
| Steven Constantine Boyages Director | Mar 18, 2026 | Award | +5,000 | – | – | 5,031 |
| Jonathan Scott Hurd Director | Mar 18, 2026 | Award | +5,000 | – | – | 5,006 |
| Nicola Marion Fraser Director | Mar 18, 2026 | Award | +5,000 | – | – | 5,000 |
| Spiro Kevin Sakiris Chief Financial Officer | Mar 18, 2026 | Award | +21,350 | – | – | 33,981 |
| Spiro Kevin Sakiris Chief Financial Officer | Mar 18, 2026 | Award | +9,150 | – | – | 12,631 |
| Spiro Kevin Sakiris Chief Financial Officer | Sep 25, 2024 | Award | +34,500 | – | – | 34,815 |
| Spiro Kevin Sakiris Chief Financial Officer | Sep 25, 2024 | Award | +34,500 | – | – | 34,815 |
| Harry Simeonidis Chief Executive Officer | Sep 25, 2024 | Award | +40,000 | – | – | 40,408 |
| Spiro Kevin Sakiris Chief Financial Officer | Mar 20, 2024 | Option exercise | +9,394 | – | – | 19,180 |
| Spiro Kevin Sakiris Chief Financial Officer | Oct 4, 2023 | Buy | +112,727 | – | – | 117,427 |
| Christopher Towers Director | Oct 4, 2023 | Buy | +9,090 | – | – | 9,880 |
| Harry Simeonidis CEO | Sep 1, 2023 | Buy | +50 | $1.85 | $93 | 4,180 |
| Harry Simeonidis CEO | Aug 31, 2023 | Buy | +100 | $1.92 | $192 | 4,130 |
| Spiro Kevin Sakiris Chief Financial Officer | May 10, 2023 | Conversion | +2,399 | $5.80 | $13.91K | 4,745 |
| Spiro Kevin Sakiris Chief Financial Officer | Oct 10, 2022 | Award | +75,000 | – | – | 125,228 |
| George Margelis Director | Oct 10, 2022 | Award | +15,000 | – | – | 15,000 |
| Harry Simeonidis President | Oct 10, 2022 | Award | +80,000 | – | – | 80,600 |
| Jonathan Scott Hurd Director | Oct 10, 2022 | Award | +15,000 | – | – | 15,000 |
| Christopher Towers Director | Oct 10, 2022 | Award | +15,000 | – | – | 15,800 |
| Steven Constantine Boyages Interim CEO and Chairperson, Director | Oct 10, 2022 | Award | +75,000 | – | – | 75,000 |
| Lawrence B. Fisher Director | Oct 10, 2022 | Award | +15,000 | – | – | 15,000 |
| Spiro Kevin Sakiris Chief Financial Officer | Jun 22, 2022 | Buy | +5,000 | $0.65 | $3.25K | 50,228 |
| Spiro Kevin Sakiris ChiefFinancial Officer | Jun 17, 2022 | Buy | +15,970 | $0.61 | $9.74K | 45,228 |
| Science Biosensor Diagnostics Pty Ltd Life – | Feb 17, 2022 | Sale | −576,028 | $0.51 | $293.77K | 1,081,804 |
| Science Biosensor Diagnostics Pty Ltd Life 10% owner | Feb 16, 2022 | Sale | −100,000 | $0.63 | $63.00K | 1,657,832 |
| Science Biosensor Diagnostics Pty Ltd Life 10% owner | Feb 15, 2022 | Sale | −100,000 | $0.68 | $68.00K | 1,757,832 |
| Science Biosensor Diagnostics Pty Ltd Life 10% owner | Feb 14, 2022 | Sale | −100,000 | $0.70 | $70.00K | 1,857,832 |
| Science Biosensor Diagnostics Pty Ltd Life 10% owner | Feb 11, 2022 | Sale | −100,000 | $0.75 | $75.00K | 1,957,832 |
| Science Biosensor Diagnostics Pty Ltd Life 10% owner | Feb 10, 2022 | Sale | −100,000 | $0.84 | $84.00K | 2,057,832 |
| Science Biosensor Diagnostics Pty Ltd Life 10% owner | Feb 9, 2022 | Sale | −100,000 | $0.86 | $86.00K | 2,157,832 |
| Science Biosensor Diagnostics Pty Ltd Life 10% owner | Feb 8, 2022 | Sale | −100,000 | $0.89 | $89.00K | 2,257,832 |
| Science Biosensor Diagnostics Pty Ltd Life 10% owner | Feb 2, 2022 | Sale | −100,000 | $0.92 | $92.00K | 2,357,832 |
| Science Biosensor Diagnostics Pty Ltd Life 10% owner | Jan 31, 2022 | Sale | −100,000 | $0.90 | $90.00K | 2,457,832 |
| Science Biosensor Diagnostics Pty Ltd Life 10% owner | Jan 28, 2022 | Sale | −100,000 | $0.92 | $92.00K | 2,557,832 |
| Science Biosensor Diagnostics Pty Ltd Life 10% owner | Jan 27, 2022 | Sale | −100,000 | $1.00 | $100.00K | 2,657,832 |
| Tom Parmakellis Director | Dec 30, 2021 | Buy | +4,500 | $1.55 | $6.98K | 9,300 |
| Science Biosensor Diagnostics Pty Ltd Life 10% owner | Dec 17, 2021 | Sale | −200,000 | $1.49 | $298.00K | 2,757,832 |
| Tom Parmakellis Director | Dec 16, 2021 | Buy | +2,800 | $1.69 | $4.73K | 4,800 |
| Spiro Kevin Sakiris ChiefFinancial Officer | Dec 6, 2021 | Buy | +10,000 | $1.70 | $17.00K | 29,258 |
| Science Biosensor Diagnostics Pty Ltd Life 10% owner | Nov 30, 2021 | Sale | −250,000 | $1.87 | $467.50K | 2,957,832 |
| Science Biosensor Diagnostics Pty Ltd Life 10% owner | Nov 29, 2021 | Sale | −100,000 | $1.69 | $169.00K | 3,207,832 |
| Science Biosensor Diagnostics Pty Ltd Life 10% owner | Nov 24, 2021 | Sale | −100,000 | $1.64 | $164.00K | 3,307,832 |
| Science Biosensor Diagnostics Pty Ltd Life 10% owner | Nov 9, 2021 | Sale | −300,000 | $2.02 | $606.00K | 3,407,832 |
| Science Biosensor Diagnostics Pty Ltd Life 10% owner | Oct 21, 2021 | Sale | −248,416 | $2.26 | $561.42K | 3,707,832 |
| Science Biosensor Diagnostics Pty Ltd Life 10% owner | Oct 20, 2021 | Sale | −24,209 | $2.25 | $54.47K | 3,956,248 |
| Science Biosensor Diagnostics Pty Ltd Life 10% owner | Oct 19, 2021 | Sale | −16,326 | $2.25 | $36.73K | 3,980,457 |
| Science Biosensor Diagnostics Pty Ltd Life 10% owner | Oct 14, 2021 | Sale | −100,726 | $2.18 | $219.58K | 3,996,783 |
| Science Biosensor Diagnostics Pty Ltd Life 10% owner | Oct 13, 2021 | Sale | −58,739 | $2.25 | $132.16K | 4,097,509 |
| Science Biosensor Diagnostics Pty Ltd Life 10% owner | Oct 12, 2021 | Sale | −100,000 | $2.13 | $213.00K | 4,156,248 |
| Science Biosensor Diagnostics Pty Ltd Life 10% owner | Oct 8, 2021 | Sale | −200,000 | $2.30 | $460.00K | 4,256,248 |
| Tom Parmakellis Director | Sep 28, 2021 | Buy | +1,000 | $2.40 | $2.40K | 2,000 |
| Science Biosensor Diagnostics Pty Ltd Life 10% owner | Sep 28, 2021 | Sale | −200,000 | $2.48 | $496.00K | 4,456,248 |
| Science Biosensor Diagnostics Pty Ltd Life 10% owner | Sep 24, 2021 | Sale | −200,000 | $2.66 | $532.00K | 4,656,248 |
| Science Biosensor Diagnostics Pty Ltd Life 10% owner | Sep 23, 2021 | Sale | −100,000 | $2.77 | $277.00K | 4,856,248 |
| Science Biosensor Diagnostics Pty Ltd Life 10% owner | Sep 22, 2021 | Sale | −100,000 | $2.80 | $280.00K | 4,956,248 |
| Science Biosensor Diagnostics Pty Ltd Life 10% owner | Sep 21, 2021 | Sale | −100,000 | $2.83 | $283.00K | 5,056,248 |
| Science Biosensor Diagnostics Pty Ltd Life 10% owner | Sep 20, 2021 | Sale | −100,000 | $2.90 | $290.00K | 5,156,248 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Intelligent Bio Solutions's stock actually held short. Settlement fails (shares not delivered on time) peaked at 59,283 shares on Sep 2, 2026 over the last 90 days.
See a number that looks wrong?